Rapamycin
Rapamycin
Rapamycin
| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-1104-10MG | Rapamycin | 10mg | $110.00 | |
| GBM-1104-50MG | Rapamycin | 50mg | $441.00 |
-
Description
mTOR inhibitor
-
Specifications
Bioassays Specification Bio-Activity mTOR inhibitor Chemical Name (7E,15E,17E,19E)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34aS-Hexadecahydro-9R,27-dihydroxy-3S-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10R,21S-dimethoxy-6R,8,12R,14S,20,26R-hexamethyl-23S,27R-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone Function / Pharmacology Clinically useful immunosuppressant. Inhibits the response to interleukin-2 blocking activation of T- and B-cells.1 Rapamycin forms a complex with cytosolic FK-binding protein 12 (FKB12) that binds to mTOR Complex1(mTORC1) inhibiting the mammalian target of rapamycin (mTOR).2 Also binds to mTORC2 leading to decreased glucose tolerance and insensitivity to insulin.3 Induces autophagy.4 CAS# 53123-88-9 MW 914.17 Molecular Formula C51H79NO13 Solubility Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 90 mg/ml). Supplied powder Storage as supplied -20°C Ship temp Ambient References 1) Kay, et al. (1991) Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72 544 / 2) Mita, et al., (2003) The molecular target of rapamycin (mTOR) as a therapeutic target against cancer Cancer Biol. Ther. 2(4 Suppl 1), S169 / 3) Lamming, et al. ( 2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335 1638 / 4) Sarkar et.al. (2009), Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies Cell Death and Differentiation 16, 46 Antibody Specification Alternate Names Sirolimus; AY-22989; WY-090217; NSC-226080; Rapamune Protein Specification Purity >98% - Reviews
| Bioassays Specification | |
| Bio-Activity | mTOR inhibitor |
| Chemical Name | (7E,15E,17E,19E)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34aS-Hexadecahydro-9R,27-dihydroxy-3S-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10R,21S-dimethoxy-6R,8,12R,14S,20,26R-hexamethyl-23S,27R-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone |
| Function / Pharmacology | Clinically useful immunosuppressant. Inhibits the response to interleukin-2 blocking activation of T- and B-cells.1 Rapamycin forms a complex with cytosolic FK-binding protein 12 (FKB12) that binds to mTOR Complex1(mTORC1) inhibiting the mammalian target of rapamycin (mTOR).2 Also binds to mTORC2 leading to decreased glucose tolerance and insensitivity to insulin.3 Induces autophagy.4 |
| CAS# | 53123-88-9 |
| MW | 914.17 |
| Molecular Formula | C51H79NO13 |
| Solubility | Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 90 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Kay, et al. (1991) Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72 544 / 2) Mita, et al., (2003) The molecular target of rapamycin (mTOR) as a therapeutic target against cancer Cancer Biol. Ther. 2(4 Suppl 1), S169 / 3) Lamming, et al. ( 2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335 1638 / 4) Sarkar et.al. (2009), Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies Cell Death and Differentiation 16, 46 |
| Antibody Specification | |
| Alternate Names | Sirolimus; AY-22989; WY-090217; NSC-226080; Rapamune |
| Protein Specification | |
| Purity | >98% |